"
ROS1 in Squamous Non-Small Cell Lung Cancer—Combined Immunotherapy (PD1/CTLA4) or Targeted Therapy?"
written by Alexander Yakobson, Tal Mor, Levitas Dina, Laila C. Roisman, Daniel Levin, Wafeek Alguayn, Sara Morgenstern, Keren Rouvinov, Nir Peled, Waleed Kian,
published by
Journal of Cancer Therapy,
Vol.11 No.6, 2020
has been cited by the following article(s):
|
[1]
|
Cost-effectiveness analysis of penpulimab plus carboplatin-paclitaxel as first-line treatment for metastatic squamous non-small-cell lung cancer in China
Health Economics Review,
2025
DOI:10.1186/s13561-025-00656-1
|
|
|
|
|
[2]
|
Profound neutrophilia as the presenting sign of GCSF-secreting, ROS1-mutant squamous cell lung cancer
BMJ Case Reports,
2025
DOI:10.1136/bcr-2025-267778
|
|
|
|
|
[3]
|
First Report of Entrectinib as a Treatment Option for Pure Squamous Cell Carcinoma Harboring ROS1 Rearrangement: Exploring the Role of Next-Generation Sequencing in Targeted Therapy
International Journal of Molecular Sciences,
2025
DOI:10.3390/ijms27010025
|
|
|
|
|
[4]
|
A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)
Cancer Cell,
2024
DOI:10.1016/j.ccell.2023.12.004
|
|
|
|